GCM Grosvenor 株価情報 (NASDAQ: GCMG)

最新ニュース GCM Grosvenor (NASDAQ:GCMG) 株価情報

GCM Grosvenor

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

GCM Grosvenor Inc. - Class A Common Stock

GCM Grosvenor Inc

Citigroup analyst Ryan Levine maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and lowers the price target from $24 to $10.

News

Price Target

Analyst Ratings

FLNC

Citigroup Maintains Neutral on Fluence Energy, Lowers Price Target to $10

WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) shares are <a href="https://www.benzinga.com/pressreleases/25/02/n43620637/wk-kellogg-co-announces-fourth-quarter-and-full-year-2024-financial-results-provides-2025-financia" target="_blank" rel="noreferrer noopener">trading lower on Tuesday.</a>
WK Kellogg reported <a target="_blank" href="https://s203.q4cdn.com/450659508/files/doc_financials/2024/q4/KLG-2024-Q4-Exhibit-99-1-Final.pdf" rel="noreferrer noopener">fourth-quarter</a> adjusted earnings per share of 42 cents, beating the street view of 26 cents. Quarterly sales of $640 million (down 1.8%) missed the analyst consensus estimate of $641.69 million.
In the fourth quarter, price/mix increased by 3.8%, but volume dropped by 5.6%. The net sales decline was due to a tough business environment and the weak Canadian Dollar against the U.S. Dollar.
The company reported adjusted EBITDA of $57 million, up 7.5% year over year. Adjusted EBITDA margin expanded to 8.9% from 8.2%.
Fourth quarter reported net income was $19 million, a 26.7% increase year-over-year. These increases reflect improved productivity and reduced waste within its supply chain operations.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43627318/whats-going-on-with-carvana-stock-today-3" rel="noreferrer noopener">What&#8217;s Going On With Carvana Stock Today?</a>
WK Kellogg exited the quarter with cash and equivalents worth $40 million and inventories worth $353 million. Long-term debt as of quarter end stood at $460 million.
As previously announced on February 6 2025, the company approved a 3% increase in its quarterly dividend to $0.165, up from $0.16 per share.
The dividend will be paid on March 14 to shareholders of record on February 28.
Outlook: Kellogg&#8217;s 2025 organic net sales are expected to decline by about 1.0%. Adjusted EBITDA growth for <a href="https://www.benzinga.com/calendars/guidance">2025 is projected to be between 4.0% and 6.0%.</a>
Price Action: KLG shares are trading lower by 0.67% to $16.20 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43614105/activist-investor-elliott-builds-25-billion-stake-in-phillips-66-pressures-for-midstream-spinoff-report" target="_blank" rel="noreferrer noopener">Activist Investor Elliott Builds $2.5 Billion Stake In Phillips 66, Pressures For Midstream Spinoff: Report</a></li>
</ul>

Earnings

Equities

Guidance

Dividends

Markets

Movers

General

WK Kellogg Q4: EPS Beat, Sales Miss Amid Challenging Market Conditions

Raymond James analyst Laura Prendergast downgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Outperform to Market Perform.

Downgrades

THRD

Raymond James Downgrades Third Harmonic Bio to Market Perform

<a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a>

Macro Economic Events

Economics

Federal Reserve

Powell Says Support Efforts To Create Regulatory Framework Around Stablecoins

Trading Ideas

AIFF

Firefly Neuroscience Shares Resume Trade

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, <a target="_blank" href="https://www.benzinga.com/quote/NVS" rel="noreferrer noopener">clinical-stage biopharmaceutical company</a>.
Anthos is developing abelacimab, a late-stage medicine to prevent stroke and systemic embolism in patients with atrial fibrillation, a type of irregular heartbeat, or arrhythmia, that occurs when the upper chambers of the heart beat irregularly.
Novartis will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront" rel="noreferrer noopener">pay</a> an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.
The transaction is expected to close in the first half of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43380284/novartis-q4-earnings-beat-estimates-ceo-dismisses-entresto-patent-expiration-worries" rel="noreferrer noopener">Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries</a>
The transaction aligns with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.
Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.
Abelacimab is a fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Phase 2 data showed a significant reduction in bleeding events in patients taking abelacimab versus a standard-of-care direct-oral anticoagulant in patients with atrial fibrillation.
Three Phase 3 trials are ongoing for patients at risk of arterial and venous clots, one in patients with atrial fibrillation and two in cancer-associated thrombosis.
In July 2022 abelacimab received an FDA Fast Track Designation for thrombosis associated with cancer.
In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
In November, Novartis acquired&nbsp;Kate Therapeutics to enhance and strengthen its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42115127/novartis-confident-in-growth-as-it-elevates-midterm-sales-forecast-ceo-narasimhan-highlights-robust-pipeline-supporting-long-term-strategy" rel="noreferrer noopener">portfolio of gene therapies</a>.
Kate Therapeutics is a San Diego-based, preclinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases.
The transaction value is up to $1.1 billion, comprising an upfront payment and potential additional milestone payments.
Price Action: NVS stock is down 0.31% at $106.52 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43611591/behind-marvell-techs-multi-fold-growth-rd-acquisitions-and-ai-infrastructure" target="_blank" rel="noreferrer noopener">Behind Marvell Tech&#8217;s Multi-Fold Growth: R&amp;D, Acquisitions And AI Infrastructure</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal

Firefly Neuroscience Shares Halted On A Circuit Breaker To The Upside, Stock Now Up 119.7%

Tigress Financial analyst Ivan Feinseth maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Strong Buy and raises the price target from $645 to $935.

Tigress Financial Maintains Strong Buy on Meta Platforms, Raises Price Target to $935

Investors with a lot of money to spend have taken a bullish stance on Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Tempus AI.
This isn't normal.
The overall sentiment of these big-money traders is split between 64% bullish and 16%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $381,921, and 17 are calls, for a total amount of $1,059,960.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $85.0 for Tempus AI over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Tempus AI's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Tempus AI's substantial trades, within a strike price spectrum from $50.0 to $85.0 over the preceding 30 days.
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289638_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.3</td>
<td>$3.6</td>
<td>$79.00</td>
<td>$174.6K</td>
<td>5</td>
<td align="right">512</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$15.9</td>
<td>$15.0</td>
<td>$15.18</td>
<td>$60.00</td>
<td>$151.8K</td>
<td>2.5K</td>
<td align="right">107</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$12.7</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$85.00</td>
<td>$125.0K</td>
<td>7</td>
<td align="right">447</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$7.7</td>
<td>$6.7</td>
<td>$7.19</td>
<td>$67.00</td>
<td>$122.2K</td>
<td>599</td>
<td align="right">269</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.0</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$55.00</td>
<td>$77.7K</td>
<td>273</td>
<td align="right">385</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Following our analysis of the options activities associated with Tempus AI, we pivot to a closer look at the company's own performance.
<h3>Tempus AI's Current Market Status</h3>
<ul>
<li>With a trading volume of 15,942,711, the price of TEM is up by 6.88%, reaching $73.06.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $60.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from TD Cowen lowers its rating to Buy with a new price target of $74. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $56. 
&#x2A; An analyst from Loop Capital has decided to maintain their Buy rating on Tempus AI, which currently sits at a price target of $52. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on Tempus AI: Analyzing the Surge in Options Activity

Powell Says Can't Give An Exact Number, Still Have A Ways To Go; Would Use Quantitative Easing Only When Rates Are At Zero

Whales with a lot of money to spend have taken a noticeably bullish stance on Marvell Tech.
Looking at options history for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $523,770 and 9, calls, for a total amount of $741,965.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $72.5 to $150.0 for Marvell Tech over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Marvell Tech's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Marvell Tech's whale activity within a strike price range from $72.5 to $150.0 in the last 30 days. 
<h3>Marvell Tech Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289633_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.75</td>
<td>$8.65</td>
<td>$8.65</td>
<td>$100.00</td>
<td>$173.8K</td>
<td>1.3K</td>
<td align="right">201</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.7</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$109.00</td>
<td>$155.2K</td>
<td>164</td>
<td align="right">500</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.55</td>
<td>$15.4</td>
<td>$15.4</td>
<td>$115.00</td>
<td>$154.0K</td>
<td>623</td>
<td align="right">401</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$23.75</td>
<td>$22.9</td>
<td>$22.95</td>
<td>$115.00</td>
<td>$114.7K</td>
<td>745</td>
<td align="right">104</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$23.1</td>
<td>$22.85</td>
<td>$22.85</td>
<td>$115.00</td>
<td>$114.2K</td>
<td>745</td>
<td align="right">54</td>
</tr>
</tbody>
</table>

<h3>About Marvell Tech</h3>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
In light of the recent options history for Marvell Tech, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Marvell Tech</h3>
<ul>
<li>Trading volume stands at 2,401,878, with MRVL's price down by -1.03%, positioned at $111.64.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 22 days.</li>
</ul>
<h3>Professional Analyst Ratings for Marvell Tech</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $134.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Marvell Tech, targeting a price of $135. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Marvell Tech, targeting a price of $113. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Marvell Tech, which currently sits at a price target of $150. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Marvell Tech, targeting a price of $140. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Marvell Tech, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MRVL

A Closer Look at Marvell Tech's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Palantir Technologies.
Looking at options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) we detected 56 trades.
If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $631,534 and 41, calls, for a total amount of $2,033,681.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $67.5 to $145.0 for Palantir Technologies during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Palantir Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palantir Technologies's whale activity within a strike price range from $67.5 to $145.0 in the last 30 days. 
<h3>Palantir Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289627_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$117.00</td>
<td>$144.2K</td>
<td>4.3K</td>
<td>5.8K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.35</td>
<td>$17.0</td>
<td>$17.35</td>
<td>$130.00</td>
<td>$140.5K</td>
<td>1.0K</td>
<td>81</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.82</td>
<td>$2.7</td>
<td>$2.76</td>
<td>$125.00</td>
<td>$136.4K</td>
<td>4.2K</td>
<td>957</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$118.00</td>
<td>$133.2K</td>
<td>4.5K</td>
<td>531</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.15</td>
<td>$9.9</td>
<td>$10.15</td>
<td>$110.00</td>
<td>$101.5K</td>
<td>7.8K</td>
<td>289</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
Following our analysis of the options activities associated with Palantir Technologies, we pivot to a closer look at the company's own performance.
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>Trading volume stands at 39,015,039, with PLTR's price down by -0.82%, positioned at $115.69.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>What The Experts Say On Palantir Technologies</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $93.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Palantir Technologies, targeting a price of $110. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Neutral rating on Palantir Technologies with a target price of $98. 
&#x2A; An analyst from Baird persists with their Neutral rating on Palantir Technologies, maintaining a target price of $100. 
&#x2A; Maintaining their stance, an analyst from Northland Capital Markets continues to hold a Market Perform rating for Palantir Technologies, targeting a price of $80. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Underperform rating on Palantir Technologies with a target price of $80. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Palantir Technologies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

PLTR

Behind the Scenes of Palantir Technologies's Latest Options Trends

Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) has outperformed the market over the past 10 years by 1.49% on an annualized basis producing an average annual return of 12.62%. Currently, Cboe Global Markets has a market capitalization of $21.51 billion. 
Buying $100 In CBOE: If an investor had bought $100 of CBOE stock 10 years ago, it would be worth $328.22 today based on a price of $205.48 for CBOE at the time of writing.
<h3>Cboe Global Markets's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBOE

Here's How Much You Would Have Made Owning Cboe Global Markets Stock In The Last 10 Years

Fed Chair Powell Says Reserves Are Still Abundant; Shrinking Balance Sheet Is Ongoing

Rosenblatt analyst Steve Frankel maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and lowers the price target from $16 to $12.

HLIT

Rosenblatt Maintains Buy on Harmonic, Lowers Price Target to $12

JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Market Perform to Market Perform.

Reiteration

INCY

JMP Securities Reiterates Market Perform on Incyteto Market Perform

Government

Politics

U.S. Needs To Spend More On Defense Than It Did Under The Biden Administration; U.S. Not Sending Troops Into Ukraine

Jones Trading analyst Soumit Roy upgrades IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) from Hold to Buy and announces $1.2 price target.

Upgrades

INAB

Jones Trading Upgrades IN8bio to Buy, Announces $1.2 Price Target

Fed Chair Powell Says Stand By Previous Comments That Countries That Have Free Trade Grow Faster; Standard Case For Free Trade Still Makes Sense, But Didnt Work That Well When Have One Large Country That Didnt Play By The Rules; Not For Fed To Comment On Tariff Policy; Clearly Not Allowed Under The Law For President To Remove A Fed Board Member

JMP Securities analyst Roy Buchanan maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Market Outperform and lowers the price target from $7 to $4.

ESPR

JMP Securities Maintains Market Outperform on Esperion Therapeutics, Lowers Price Target to $4

Reports Q4 revenue $165.3M, consensus $161.1M. "We ended 2024 on a high note, capping a year of strong investment returns, a 41% increase in annual...

GCM Grosvenor reports Q4 adjusted EPS 27c, consensus 23c

In February 2025, GCM Grosvenor's (GCMG) Board of Directors increased the firm's existing share repurchase authorization by $50 million, from $140 ...

GCM Grosvenor board increases share repurchase authorization for $190M

GCM Grosvenor declares $0.11 dividend

GCM Grosvenor ( ($GCMG) ) just unveiled an announcement. On February 6, 2025, GCM Grosvenor's Board of Directors appointed David A. Helfand to its ...

GCM Grosvenor Appoints David A. Helfand to Board

GCM Grosvenor Inc. 2024 Q4 - Results - Earnings Call Presentation

GCM Grosvenor targets $7.1B fundraising in 2024 with growing momentum into 2025

GCM Grosvenor Inc. (GCMG) Q4 2024 Earnings Call Transcript

Gcm Grosvenor Inc. (($GCMG)) has held its Q4 earnings call. Read on for the main highlights of the call. GCM Grosvenor Inc. recently held its earni...

GCM Grosvenor Shines in Earnings Call with Strong Growth

Gcm Grosvenor Inc. ( ($GCMG) ) has released its Q4 earnings. Here is a breakdown of the information Gcm Grosvenor Inc. presented to its investors. ...

GCM Grosvenor Inc. Reports Strong 2024 Earnings

J.P. Morgan analyst Ken Worthington maintained a Hold rating on GCM Grosvenor (GCMG – Research Report) yesterday and set a price target of $14.00. ...

J.P. Morgan Remains a Hold on GCM Grosvenor (GCMG)

GCMG

GCMGW

Press Releases

GCM Grosvenor Reports Third Quarter 2024 Earnings Results, with Year-to-Date Fundraising Increasing 34%, and Year-to-Date GAAP Net Income, Fee-Related Earnings and Adjusted Net Income Increasing 16%, 18% and 24%, Respectively, Year-Over-Year

CION Investments and GCM Grosvenor Announce SEC Effectiveness of the CION Grosvenor Infrastructure Fund

Financing

AGT Food and Ingredients Inc. Announces Sale of Shortline Rail and Bulk Handling Infrastructure; Partnership with GCM Grosvenor and Mobil Grain Ltd.

GCM Grosvenor Elevate Fund Holds Final Close at Nearly $800 Million, the Largest Debut Private Equity Seeding Fund of Its Kind, Signaling Strong Continued Support for Small and Emerging Firm Founders

GCM Grosvenor to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Investor Conference Call on February 10, 2025

GCM Grosvenor to Present at the UBS Financial Services Conference on February 11, 2025

CION Investments and GCM Grosvenor Announce Launch of the CION Grosvenor Infrastructure Fund with $240 Million Invested in Infrastructure Assets

GCM Grosvenor to Present at the Bank of America Securities Financial Services Conference on February 12, 2025

Management

GCM Grosvenor Expands Insurance Solutions Group with the Hire of Joe Metzger as Managing Director

GCM Grosvenor Reports Fourth Quarter and Full Year 2024 Earnings Results, with 2024 Fundraising Increasing 41%, and Year-to-Date GAAP Net Income, Fee-Related Earnings and Adjusted Net Income Increasing 46%, 19% and 36%, Respectively, Year-Over-Year

Comments

GCM Grosvenor

ニュース

最新ニュース GCM Grosvenor (NASDAQ:GCMG) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル